The future of renoprotection: Frustration and promises

[1]  A. Collins,et al.  Projecting the number of patients with end-stage renal disease in the United States to the year 2015. , 2005, Journal of the American Society of Nephrology : JASN.

[2]  N. Perico,et al.  Targeted Deletion of Angiotensin Ii Type 1a Receptor Does Not Protect Mice from Progressive Nephropathy of Overload Proteinuria , 2022 .

[3]  A. Salam.  Selective aldosterone blockade with eplerenone in patients with congestive heart failure , 2003, Expert opinion on investigational drugs.

[4]  N J Wald,et al.  Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials , 2003, BMJ : British Medical Journal.

[5]  Ü. Pechter,et al.  Beneficial effects of water-based exercise in patients with chronic kidney disease. , 2003 .

[6]  G. Remuzzi,et al.  Proteinuria and phenotypic change of proximal tubular cells. , 2003, Journal of the American Society of Nephrology : JASN.

[7]  M. Toungouz,et al.  Tolerance induction in clinical transplantation: the pending questions , 2003, Transplantation.

[8]  A. Fogo.  The potential for regression of renal scarring. , 2003, Current opinion in nephrology and hypertension.

[9]  N. Perico,et al.  Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries. , 2003, Kidney international.

[10]  H. Morita,et al.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. , 2003, Lancet.

[11]  H. Morita,et al.  RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial , 2003, The Lancet.

[12]  T. Hostetter.  The next treatments of chronic kidney disease: if we find them, can we test them? , 2002, Journal of the American Society of Nephrology : JASN.

[13]  G. Remuzzi,et al.  Transforming Growth Factor- (cid:1) 1 Is Up-Regulated by Podocytes in Response to Excess Intraglomerular Passage of Proteins A Central Pathway in Progressive Glomerulosclerosis , 2022 .

[14]  G. Remuzzi,et al.  How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. , 2002, Journal of the American Society of Nephrology : JASN.

[15]  Joel Lexchin,et al.  The pharmaceutical industry as a medicines provider , 2002, The Lancet.

[16]  C. Donadoni,et al.  Effect of angiotensin II antagonism on the regression of kidney disease in the rat. , 2002, Kidney international.

[17]  V. Kher.  End-stage renal disease in developing countries. , 2002, Kidney international.

[18]  G. Remuzzi,et al.  The renin-angiotensin system in progression, remission and regression of chronic nephropathies. , 2002, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[19]  G. Remuzzi,et al.  Protein Overload-Induced NF-κB Activation in Proximal Tubular Cells Requires H2O2 through a PKC-Dependent Pathway , 2002 .

[20]  M. Dichgans.  CADASIL: A Monogenic Condition Causing Stroke and Subcortical Vascular Dementia , 2002, Cerebrovascular Diseases.

[21]  Lysaght Mj,et al.  Maintenance Dialysis Population Dynamics: Current Trends and Long-Term Implications , 2002 .

[22]  H. Parving.  Diabetic nephropathy: prevention and treatment. , 2001, Kidney international.

[23]  J. Egido,et al.  Tubular NF-κB and AP-1 activation in human proteinuric renal disease , 2001 .

[24]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[25]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[26]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[27]  C. Schmid,et al.  Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease , 2001, Annals of Internal Medicine.

[28]  V. Torres,et al.  Treatment prospects for autosomal-dominant polycystic kidney disease. , 2001, Kidney international.

[29]  G. Remuzzi,et al.  Progression, remission, regression of chronic renal diseases , 2001, The Lancet.

[30]  A. Eddy.  Role of cellular infiltrates in response to proteinuria. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  B. Kasiske,et al.  Effect of lipid reduction on the progression of renal disease: a meta-analysis. , 2001, Kidney international.

[32]  A. Baldwin.  Series Introduction: The transcription factor NF-κB and human disease , 2001 .

[33]  G. Remuzzi,et al.  Protein traffic activates NF-kB gene signaling and promotes MCP-1-dependent interstitial inflammation. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[34]  G. Wolf.  Involvement of Angiotensin II in Tubulointerstitial Disease Angiotensin II as a mediator of tubulointerstitial injury , 2000 .

[35]  G. Remuzzi,et al.  Strategies for making more organs available for transplantation. , 2000, The New England journal of medicine.

[36]  R. Kalluri,et al.  Angiotensin II Induces α3(IV) Collagen Expression in Cultured Murine Proximal Tubular Cells , 1999 .

[37]  F. Strutz,et al.  Interstitial Pathomechanisms Underlying Progressive Tubulointerstitial Damage , 1999, Kidney and Blood Pressure Research.

[38]  N. Perico,et al.  Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease. , 1999, Journal of the American Society of Nephrology : JASN.

[39]  G. Remuzzi,et al.  Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade. , 1999, Kidney international.

[40]  G. Remuzzi,et al.  Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial , 1998, The Lancet.

[41]  R. Baxter,et al.  Paracrine stimulation of human renal fibroblasts by proximal tubule cells. , 1998, Kidney international.

[42]  C. Wanner,et al.  Smoking as a risk factor for end-stage renal failure in men with primary renal disease. , 1998, Kidney international.

[43]  G. Remuzzi,et al.  Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. , 1998, Kidney international.

[44]  M. Mani.  The management of end-stage renal disease in India. , 1998, Artificial organs.

[45]  G. Wolf,et al.  Renal tubular hypertrophy induced by angiotensin II. , 1997, Seminars in nephrology.

[46]  J. Gloy,et al.  Angiotensin II depolarizes podocytes in the intact glomerulus of the Rat. , 1997, The Journal of clinical investigation.

[47]  M. Karin,et al.  Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. , 1997, The New England journal of medicine.

[48]  C. Caserta,et al.  Alternative pathway complement activation induces proinflammatory activity in human proximal tubular epithelial cells. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[49]  N. Perico,et al.  Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. , 1996, Journal of the American Society of Nephrology : JASN.

[50]  J. Egido.  Vasoactive hormones and renal sclerosis. , 1996, Kidney international.

[51]  H. Schnaper,et al.  ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. , 1995, Kidney international.

[52]  W. Kriz,et al.  A role for podocytes to counteract capillary wall distension. , 1994, Kidney international.

[53]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[54]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[55]  N. Perico,et al.  Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. , 1993, Journal of the American Society of Nephrology : JASN.

[56]  G. Remuzzi,et al.  Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. , 1990, The Journal of clinical investigation.

[57]  G. Remuzzi,et al.  Age-related nephropathy and proteinuria in rats with intact kidneys exposed to diets with different protein content. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[58]  D. Salant,et al.  Role of Abnormally High Transmural Pressure in the Permselectivity Defect of Glomerular Capillary Wall: A Study in Early Passive Heymann Nephritis , 1987, Circulation research.

[59]  G. Remuzzi,et al.  Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. , 1986, Kidney international.

[60]  B. Brenner,et al.  Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. , 1986, The Journal of clinical investigation.

[61]  B. Brenner,et al.  Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. , 1986, The Journal of clinical investigation.

[62]  W. Keane,et al.  Relationship among altered glomerular barrier permselectivity, angiotensin II, and mesangial uptake of macromolecules. , 1985, Laboratory investigation; a journal of technical methods and pathology.

[63]  B. Brenner,et al.  Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. , 1982, The New England journal of medicine.